Humacyte Statistics
Total Valuation
Humacyte has a market cap or net worth of $328.85 million. The enterprise value is $348.52 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 155.12 million shares outstanding. The number of shares has increased by 18.75% in one year.
| Current Share Class | 155.12M |
| Shares Outstanding | 155.12M |
| Shares Change (YoY) | +18.75% |
| Shares Change (QoQ) | +3.76% |
| Owned by Insiders (%) | 7.40% |
| Owned by Institutions (%) | 39.50% |
| Float | 121.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 636.08 |
| Forward PS | 25.60 |
| PB Ratio | 10.16 |
| P/TBV Ratio | 9.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 674.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.68, with a Debt / Equity ratio of 2.29.
| Current Ratio | 3.68 |
| Quick Ratio | 3.16 |
| Debt / Equity | 2.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.61 |
Financial Efficiency
Return on equity (ROE) is -249.75% and return on invested capital (ROIC) is -62.70%.
| Return on Equity (ROE) | -249.75% |
| Return on Assets (ROA) | -42.82% |
| Return on Invested Capital (ROIC) | -62.70% |
| Return on Capital Employed (ROCE) | -77.88% |
| Revenue Per Employee | $2,350 |
| Profits Per Employee | -$363,818 |
| Employee Count | 220 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.60% in the last 52 weeks. The beta is 2.00, so Humacyte's price volatility has been higher than the market average.
| Beta (5Y) | 2.00 |
| 52-Week Price Change | -57.60% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 3.70 |
| Relative Strength Index (RSI) | 41.03 |
| Average Volume (20 Days) | 3,623,073 |
Short Selling Information
The latest short interest is 28.43 million, so 18.33% of the outstanding shares have been sold short.
| Short Interest | 28.43M |
| Short Previous Month | 31.80M |
| Short % of Shares Out | 18.33% |
| Short % of Float | 23.31% |
| Short Ratio (days to cover) | 5.18 |
Income Statement
In the last 12 months, Humacyte had revenue of $517,000 and -$80.04 million in losses. Loss per share was -$0.65.
| Revenue | 517,000 |
| Gross Profit | -82.38M |
| Operating Income | -111.00M |
| Pretax Income | -105.70M |
| Net Income | -80.04M |
| EBITDA | -103.77M |
| EBIT | -111.00M |
| Loss Per Share | -$0.65 |
Full Income StatementBalance Sheet
The company has $62.85 million in cash and $82.51 million in debt, giving a net cash position of -$19.67 million or -$0.13 per share.
| Cash & Cash Equivalents | 62.85M |
| Total Debt | 82.51M |
| Net Cash | -19.67M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 36.04M |
| Book Value Per Share | 0.23 |
| Working Capital | 53.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$99.38 million and capital expenditures -$1.41 million, giving a free cash flow of -$100.79 million.
| Operating Cash Flow | -99.38M |
| Capital Expenditures | -1.41M |
| Free Cash Flow | -100.79M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -21,470.79% |
| Pretax Margin | -15,022.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.75% |
| Shareholder Yield | -18.75% |
| Earnings Yield | -24.34% |
| FCF Yield | -30.65% |
Analyst Forecast
The average price target for Humacyte is $13.00, which is 513.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 513.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Humacyte has an Altman Z-Score of -4.43. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.43 |
| Piotroski F-Score | n/a |